Bill > SB946

This bill amends Pennsylvania's Controlled Substance Act to address tianeptine, a drug currently not well-regulated in the state. Specifically, the bill adds tianeptine to Schedule II of controlled substances, which includes drugs with high potential for abuse and severe risks of psychological or physical dependence. Additionally, the bill establishes a comprehensive framework for monitoring and responding to tianeptine-related health risks. The Department of Health is now mandated to track adverse health events associated with tianeptine, collecting data from healthcare providers, hospitals, poison control centers, coroners, medical examiners, and law enforcement agencies. The department must issue public advisories about tianeptine's dangers when significant public safety threats are identified and may coordinate with local and federal agencies to protect public health. The bill extensively defines "adverse health events" related to tianeptine, which include a wide range of potential medical complications such as neurological symptoms, respiratory effects, cardiovascular issues, psychological effects, gastrointestinal symptoms, withdrawal symptoms, and potentially fatal reactions. These provisions aim to address the growing concern about tianeptine's potential health risks and provide a regulatory mechanism to monitor and mitigate its harmful effects. The bill will take effect 60 days after its passage.

Health and Social Services

https://www.legis.state.pa.us/cfdocs/billinfo/bill_history.cfm?syear=2025&sind=0&body=S&type=B&bn=946